ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Biotech Showcase In San Francisco

To register for the events or for more information, please visit Biotech Showcase's website: Dr. Laikind will review recent progress with the company's VC-01 islet replacement product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development. A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes, called STEP ONE, or ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

http://ift.tt/1GP9Nxj